Pemetrexed Injection
Product Images NDC 63759-3049

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 63759-3049). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Shilpa Medicare Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Pemetrexed Injection 1)

Chemical structure of Pemetrexed disodium, showing the molecular arrangement including amino groups, carboxylate groups, and sodium atoms, along with 2.5 molecules of water of hydration.*

FDA Label Image

Image (Pemetrexed Injection 10)

A Kaplan-Meier survival curve graph comparing survival probability over time (up to 30 months) between two treatment groups: Pemetrexed plus Cisplatin (solid line) and Cisplatin alone (dotted line). The chart includes a table indicating the number of patients at risk at various time points for both groups.*

FDA Label Image

Vial Label (Pemetrexed Injection 11)

Label for Pemetrexed Injection 100 mg/10 mL (10 mg/mL) by Shilpa Medicare Limited. It states each mL contains 10 mg pemetrexed, recommended for intravenous infusion only. The single-dose vial label includes storage instructions, lot and expiration print area, manufacturer details, barcode, and warnings including 'Hazardous Drug' and 'Administer Undiluted.'*

FDA Label Image

Carton Label (Pemetrexed Injection 12)

Packaging label for Pemetrexed Injection 100 mg/10 mL (10 mg/mL) intravenous injection by Shilpa Medicare Limited. The label includes instructions for single dose vial use, storage conditions, and a hazardous drug warning. Manufacturer is Zydus Lifesciences Limited, India. NDC 63759-3048-1 is displayed along with barcodes and lot/expiration placeholders.*

FDA Label Image

Vial Label (Pemetrexed Injection 13)

Label for Pemetrexed Injection 500 mg/50 mL (10 mg/mL) single dose vial. Active ingredient is pemetrexed disodium equivalent to 10 mg/mL pemetrexed. Label includes storage instructions, manufacturer Zydus Lifesciences Limited, and labeler Shilpa Medicare Limited, India. It highlights use for intravenous infusion, undiluted administration, and that it is a hazardous drug.*

FDA Label Image

Carton Label (Pemetrexed Injection 14)

Packaging label for Pemetrexed Injection 500 mg/50 mL (10 mg/mL) intravenous infusion, single-dose vial. The label includes directions to administer undiluted and discard unused portion. Manufactured by Zydus Lifesciences Limited and labeled for Shilpa Medicare Limited, India. Contains barcodes, NDC 63759-3049-1, storage instructions, and notes this is a hazardous drug.*

FDA Label Image

Vial Label (Pemetrexed Injection 15)

Label for Pemetrexed Injection 1000 mg/100 mL (10 mg/mL), an intravenous injection by Shilpa Medicare Limited. The label states active ingredient concentration, storage conditions (20°C to 25°C), and usage instructions including single dose vial and discard unused portion. Manufactured by Zydus Lifesciences Limited, India. Includes lot/expiration area, barcode, and hazard warning.*

FDA Label Image

Carton Label (Pemetrexed Injection 16)

Label for Pemetrexed Injection 1,000 mg/100 mL (10 mg/mL) for intravenous infusion, single dose vial by Shilpa Medicare Limited. The label notes the concentration as 10 mg/mL and includes storage instructions, manufacturer details (Zydus Lifesciences Limited, Ahmedabad, India), and warnings to administer undiluted and that it is a hazardous drug. The label displays the NDC 63759-3050-1 and emphasizes discarding unused portions.*

FDA Label Image

.. (Pemetrexed Injection 2)

A Kaplan-Meier survival curve chart showing overall survival percentage over time in months for two treatment arms: Pemetrexed + pembrolizumab + platinum chemotherapy (P+P+C) represented by a black line, and Pemetrexed + platinum chemotherapy + placebo (P+C) represented by a gray line. The chart includes a table of patient numbers at risk for each group at various time points up to 42 months.*

FDA Label Image

Image (Pemetrexed Injection 3)

A survival probability curve comparing Pemetrexed plus Cisplatin (PC) and Gemcitabine plus Cisplatin (GC) over time in months. The chart includes a survival probability axis (0 to 1) and a timeline up to 30 months, with patient-at-risk counts at various intervals for both treatment groups.*

FDA Label Image

Image (Pemetrexed Injection 4)

A survival probability curve graph comparing Pemetrexed plus Cisplatin (PC) and Gemcitabine plus Cisplatin (GC) treatments over a 30-month period. The x-axis shows survival time in months, and the y-axis shows survival probability. Below the graph, a table lists the number of patients at risk at various time points for both treatment groups.*

FDA Label Image

Image (Pemetrexed Injection 5)

A Kaplan-Meier survival curve comparing overall survival probabilities over time (in months) between two treatment groups: Pemetrexed plus Cisplatin (solid line) and Gemcitabine plus Cisplatin (dotted line). The x-axis represents survival time up to 30 months, and the y-axis shows survival probability from 0 to 1. Patient counts at risk at various time points for each group are listed below the graph.*

FDA Label Image

Image (Pemetrexed Injection 6)

A survival probability curve comparing Pemetrexed injection with placebo over a period of 42 months. The graph shows survival probability on the y-axis and survival time in months on the x-axis, including patient counts at risk for both Pemetrexed and placebo groups at various time points.*

FDA Label Image

Image (Pemetrexed Injection 7)

A Kaplan-Meier survival curve comparing survival probability over time in months between Pemetrexed and placebo groups. The solid line represents Pemetrexed, and the dotted line represents placebo. Below the graph is a table showing the number of patients at risk at various time points for each group.*

FDA Label Image

Image (Pemetrexed Injection 8)

A survival probability Kaplan-Meier curve comparing Pemetrexed injection versus placebo over time in months. The x-axis shows survival time from 0 to 42 months, and the y-axis shows survival probability from 0 to 1. The chart includes patient count risk tables below the curves at various time points for both Pemetrexed and placebo groups.*

FDA Label Image

Image (Pemetrexed Injection 9)

A survival probability curve chart comparing Pemetrexed injection versus placebo over time in months. The chart shows survival probability on the vertical axis and survival time on the horizontal axis, with separate lines for Pemetrexed and placebo. Additional patient risk numbers are listed below the graph at various time points for both groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.